A citation-based method for searching scientific literature

Carolyn M Langlois, Angela Bradbury, Elisabeth M Wood, J Scott Roberts, Scott Y H Kim, Marie-Emmanuelle Riviere, Fonda Liu, Eric M Reiman, Pierre N Tariot, Jason Karlawish, Jessica B Langbaum. Alzheimers Dement (N Y) 2019
Times Cited: 9







List of co-cited articles
47 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Disclosure of APOE genotype for risk of Alzheimer's disease.
Robert C Green, J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A Dessa Sadovnick, Kimberly A Quaid,[...]. N Engl J Med 2009
313
55

Helping patients decide: ten steps to better risk communication.
Angela Fagerlin, Brian J Zikmund-Fisher, Peter A Ubel. J Natl Cancer Inst 2011
296
44

Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
Joshua D Grill, Rema Raman, Karin Ernstrom, David L Sultzer, Jeffrey M Burns, Michael C Donohue, Keith A Johnson, Paul S Aisen, Reisa A Sperling, Jason Karlawish. JAMA Neurol 2020
12
44

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish. Alzheimers Res Ther 2015
50
44

Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Emily A Largent, Kristin Harkins, Christopher H van Dyck, Sara Hachey, Pamela Sankar, Jason Karlawish. PLoS One 2020
17
44

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.
Arno de Wilde, Marieke M van Buchem, René H J Otten, Femke Bouwman, Andrew Stephens, Frederik Barkhof, Philip Scheltens, Wiesje M van der Flier. Alzheimers Res Ther 2018
19
44

Safety of disclosing amyloid status in cognitively normal older adults.
Jeffrey M Burns, David K Johnson, Edward P Liebmann, Rebecca J Bothwell, Jill K Morris, Eric D Vidoni. Alzheimers Dement 2017
36
44

Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
S A S A Bemelmans, K Tromp, E M Bunnik, R J Milne, S Badger, C Brayne, M H Schermer, E Richard. Alzheimers Res Ther 2016
31
44

A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.
Robert C Green, Kurt D Christensen, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Charmaine D M Royal, Thomas O Obisesan, Robert Cook-Deegan, Erin Linnenbringer, Melissa Barber Butson,[...]. Alzheimers Dement 2015
25
33

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine,[...]. Alzheimers Dement 2011
33

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials.
Yan Zhou, David Elashoff, Sarah Kremen, Edmond Teng, Jason Karlawish, Joshua D Grill. Alzheimers Dement (N Y) 2016
37
33

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Clifford R Jack, David A Bennett, Kaj Blennow, Maria C Carrillo, Billy Dunn, Samantha Budd Haeberlein, David M Holtzman, William Jagust, Frank Jessen, Jason Karlawish,[...]. Alzheimers Dement 2018
33

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.
B R Ott, M A Pelosi, G Tremont, P J Snyder. Alzheimers Dement (N Y) 2016
15
33

On the personal utility of Alzheimer's disease-related biomarker testing in the research context.
Eline M Bunnik, Edo Richard, Richard Milne, Maartje H N Schermer. J Med Ethics 2018
13
33

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
Serena Chao, J Scott Roberts, Theresa M Marteau, Rebecca Silliman, L Adrienne Cupples, Robert C Green. Alzheimer Dis Assoc Disord 2008
156
33

Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
Sarah S Kalia, Kathy Adelman, Sherri J Bale, Wendy K Chung, Christine Eng, James P Evans, Gail E Herman, Sophia B Hufnagel, Teri E Klein, Bruce R Korf,[...]. Genet Med 2017
831
22

A polymorphic DNA marker genetically linked to Huntington's disease.
J F Gusella, N S Wexler, P M Conneally, S L Naylor, M A Anderson, R E Tanzi, P C Watkins, K Ottina, M R Wallace, A Y Sakaguchi. Nature 1983
22

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults.
Tara T Lineweaver, Mark W Bondi, Douglas Galasko, David P Salmon. Am J Psychiatry 2014
58
22

An update on genetic frontotemporal dementia.
Caroline V Greaves, Jonathan D Rohrer. J Neurol 2019
82
22

The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
Cristina Lopez Lopez, Pierre N Tariot, Angelika Caputo, Jessica B Langbaum, Fonda Liu, Marie-Emmanuelle Riviere, Carolyn Langlois, Marie-Laure Rouzade-Dominguez, Martin Zalesak, Suzanne Hendrix,[...]. Alzheimers Dement (N Y) 2019
33
22


Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.
Davis C Ryman, Natalia Acosta-Baena, Paul S Aisen, Thomas Bird, Adrian Danek, Nick C Fox, Alison Goate, Peter Frommelt, Bernardino Ghetti, Jessica B S Langbaum,[...]. Neurology 2014
228
22


The personal and clinical utility of polygenic risk scores.
Ali Torkamani, Nathan E Wineinger, Eric J Topol. Nat Rev Genet 2018
399
22

Recommendations for the predictive genetic test in Huntington's disease.
R MacLeod, A Tibben, M Frontali, G Evers-Kiebooms, A Jones, A Martinez-Descales, R A Roos. Clin Genet 2013
114
22

Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.
Joseph F Arboleda-Velasquez, Francisco Lopera, Michael O'Hare, Santiago Delgado-Tirado, Claudia Marino, Natalia Chmielewska, Kahira L Saez-Torres, Dhanesh Amarnani, Aaron P Schultz, Reisa A Sperling,[...]. Nat Med 2019
122
22

APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts.
Jing Qian, Frank J Wolters, Alexa Beiser, Mary Haan, M Arfan Ikram, Jason Karlawish, Jessica B Langbaum, John M Neuhaus, Eric M Reiman, J Scott Roberts,[...]. PLoS Med 2017
70
22

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
22


Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
Scott Y H Kim, Jason Karlawish, Benjamin E Berkman. Neurology 2015
27
22

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Jessica Mozersky, Pamela Sankar, Kristin Harkins, Sara Hachey, Jason Karlawish. JAMA Neurol 2018
30
22

Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment.
Joshua D Grill, Jason Karlawish, David Elashoff, Barbara G Vickrey. Alzheimers Dement 2013
24
22

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Yen Ying Lim, Paul Maruff, Christine Getter, Peter J Snyder. Alzheimers Dement 2016
35
22


Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.
Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris. JAMA Neurol 2015
19
22

The A4 study: stopping AD before symptoms begin?
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen. Sci Transl Med 2014
420
22

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.
L A Farrer, L A Cupples, J L Haines, B Hyman, W A Kukull, R Mayeux, R H Myers, M A Pericak-Vance, N Risch, C M van Duijn. JAMA 1997
22

Barriers and facilitators of African American participation in Alzheimer disease biomarker research.
Monique M Williams, Darcell P Scharff, Katherine J Mathews, Jonathan S Hoffsuemmer, Pamela Jackson, John C Morris, Dorothy F Edwards. Alzheimer Dis Assoc Disord 2010
50
22

Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease.
Shana D Stites, Richard Milne, Jason Karlawish. Alzheimers Dement (Amst) 2018
10
22

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
Tiia Ngandu, Jenni Lehtisalo, Alina Solomon, Esko Levälahti, Satu Ahtiluoto, Riitta Antikainen, Lars Bäckman, Tuomo Hänninen, Antti Jula, Tiina Laatikainen,[...]. Lancet 2015
22

Communicating treatment risks and benefits to cancer patients: a systematic review of communication methods.
L F van de Water, J J van Kleef, W P M Dijksterhuis, I Henselmans, H G van den Boorn, N M Vaarzon Morel, K F Schut, J G Daams, E M A Smets, H W M van Laarhoven. Qual Life Res 2020
7
28

Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.
Giovanni B Frisoni, José Luis Molinuevo, Daniele Altomare, Emmanuel Carrera, Frederik Barkhof, Johannes Berkhof, Julien Delrieu, Bruno Dubois, Miia Kivipelto, Agneta Nordberg,[...]. Alzheimers Dement 2020
10
22

Evidence-based risk communication: a systematic review.
Daniella A Zipkin, Craig A Umscheid, Nancy L Keating, Elizabeth Allen, KoKo Aung, Rebecca Beyth, Scott Kaatz, Devin M Mann, Jeremy B Sussman, Deborah Korenstein,[...]. Ann Intern Med 2014
171
22

The characterisation of subjective cognitive decline.
Frank Jessen, Rebecca E Amariglio, Rachel F Buckley, Wiesje M van der Flier, Ying Han, José Luis Molinuevo, Laura Rabin, Dorene M Rentz, Octavio Rodriguez-Gomez, Andrew J Saykin,[...]. Lancet Neurol 2020
140
22

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.
Gill Livingston, Jonathan Huntley, Andrew Sommerlad, David Ames, Clive Ballard, Sube Banerjee, Carol Brayne, Alistair Burns, Jiska Cohen-Mansfield, Claudia Cooper,[...]. Lancet 2020
585
22

Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease.
Ingrid S van Maurik, Leonie Nc Visser, Ruth E Pel-Littel, Marieke M van Buchem, Marissa D Zwan, Marleen Kunneman, Wiesje Pelkmans, Femke H Bouwman, Mirella Minkman, Niki Schoonenboom,[...]. JMIR Form Res 2019
13
22

Functional cognitive disorders: a systematic review.
Laura McWhirter, Craig Ritchie, Jon Stone, Alan Carson. Lancet Psychiatry 2020
33
22

Lewy body dementias.
Zuzana Walker, Katherine L Possin, Bradley F Boeve, Dag Aarsland. Lancet 2015
218
11

Ethics in prion disease.
Kendra Bechtel, Michael D Geschwind. Prog Neurobiol 2013
11
11

Direct-to-Consumer Testing 2.0: Emerging Models of Direct-to-Consumer Genetic Testing.
Megan A Allyse, David H Robinson, Matthew J Ferber, Richard R Sharp. Mayo Clin Proc 2018
55
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.